Quarterly biotech funding continues upward in Q2 of 2026 trend with 4th straight quarter of growth

Biotech companies raised $34.3 billion in the second quarter of 2026. That's the best quarter in almost two years, according to new data from TD Cowen.

The story in three parts

Part one: the COVID boom, then a long winter. During COVID, biotech funding shot up to $48.2 billion in one quarter (2Q20). Then it slid downhill for two years as things cooled off. By late 2022, funding had dropped all the way to $10.9 billion a quarter. People started calling this stretch the "biotech winter."

Part two: a fake spring. In January 2024, investors suddenly got excited about biotech again. Everyone who had been waiting to raise money for two years tried to do it at the same time. Funding jumped to $47.2 billion in one quarter, almost as high as the COVID peak. It wasn't one giant deal. It was just a lot of companies rushing through the door at once.

That rush didn't last. Most of the companies that went public that year lost about 70% of their value within a year and a half. Investors got burned and got scared again. So funding didn't just stay low, it dropped even lower than before, all the way down to $13.2 billion by mid-2025.

Part three: the current climb, and why it's different. Since then, funding has grown for four quarters in a row, back up to $34.3 billion. This trend seems more like a recovery than the crazy spike back in 2024, and we are optimistic for it to continue. Big pharma companies are about to lose patent protection on some of their best-selling drugs (over $230 billion worth), which means cheaper copies can flood in and wipe out their sales. So pharma companies have to buy smaller biotech companies to replace that lost revenue.

What this means for you

Money is flowing to safer, more proven companies first. Early-stage startups aren't getting funded nearly as much, in fact, new company financing (seed and Series A rounds) is at its lowest level in years, even while the overall numbers look good.

By category, cancer and immune-disease companies are getting the most funding, about a third of all biotech venture money. Six of this year's 13 biotech IPOs are in cancer or immune disease. Weight-loss drugs (GLP-1) and AI drug discovery are grabbing headlines with a few giant deals (Isomorphic Labs raised $2.1 billion, and two IPOs, Kailera and Parabilis, raised $625 million and $670 million). But those are the exceptions, not what's happening across the board.

If you work in lab tools or diagnostics, pay attention here. This part of the industry depends directly on how much biotech companies are spending, and it's been the weakest link for two years. As cancer and immune-disease drugs move closer to approval, and as weight-loss drug manufacturing ramps up, that should start showing up as more spending on tools and equipment.

Source: TD Cowen, Biotech Funding Tracker, July 8, 2026 (BioWorld data); BioPharma Dive; IQVIA; Fierce Biotech; PitchBook via BioSpace; PharmaVoice